45 results
8-K
EX-99.1
NKTR
Nektar Therapeutics
4 Mar 24
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4:20pm
2023 primarily due to the wind down of the bempegaldesleukin program.
G&A expense was $17.3 million in the fourth quarter of 2023 and $21.9 million … for the full year 2023 primarily due to the wind down of the bempegaldesleukin program.
Restructuring, impairment and other costs of the terminated program
8-K
EX-99.1
NKTR
Nektar Therapeutics
7 Nov 23
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
4:21pm
and first nine months of 2023 due to the wind down of the bempegaldesleukin program.
G&A expense was $21.1 million in the third quarter of 2023 … in the first nine months of 2022. G&A expense decreased for both the third quarter and first nine months of 2023 due to the wind down
8-K
EX-99.1
i6xlt1g uqw4ot2sl
8 Aug 23
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
1bzq16c
9 May 23
Nektar Therapeutics Reports First Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
ygnh6w
3 Nov 22
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
4:20pm
8-K
EX-99.1
q8t9615
4 Aug 22
Nektar Therapeutics Reports Second Quarter 2022 Financial Results
4:23pm
8-K
mknt9j2inva5subnu
2 May 22
Cost Associated with Exit or Disposal Activities
4:05pm
8-K
EX-99.1
krv ays311vqvbspf
25 Apr 22
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
4:40pm
8-K
h938i
14 Apr 22
Other Events
4:44pm